Antibodies
GSK3β, tumor
TUMOR
The following antihuman antibodies were used for flow cytometry analysis: CD4 (RRID:AB_1645271), CD8 (RRID:AB_893422), CD69 (RRID:AB_314846), Ki67 (RRID:AB_396302), ICOS (RRID:AB_10732348), FOXP3 (RRID:AB_1518782), PD-1 (RRID:AB_940475), CD25 (RRID:AB_11218989), CD45 (RRID:AB_1645452), and CD3 (RRID:AB_493741). The following anti-mouse antibodies were used for flow cytometry analysis: CD3 (RRID:AB_394595), CD4 (RRID:AB_393977), CD8 (RRID:AB_1645237), CD25 (RRID:AB_394509), FOXP3 (RRID:AB_469457), ICOS (RRID:AB_2562545), Ki67 (RRID:AB_2564285), PD-1 (RRID:AB_57201), T-bet (RRID:AB_10564071), granzyme B (RRID:AB_2294995), CD127 (RRID:AB_1937216), CD45 (RRID:AB_2737976), and CD44 (RRID:AB_10895752). All human and murine flow cytometry studies incorporated fixable Near IR Live/Dead (Invitrogen) dye to assess viability.For Western-based characterization of protein kinase B (AKT) signaling, antibodies against pAKT (RRID:AB_2315049), total AKT (RRID:AB_329827), pGSK3β (RRID:AB_10013750), total GSK3β (RRID:AB_2636978), and ICOS (discontinued, no RRID) were used. The following antibodies were used for immunofluorescence of case study tumor samples: ICOS (RRID:AB_10710236), PD-1 (RRID:AB_2894867), PD-L1 (RRID:AB_2827816), OX40/CD134 (RRID:AB_10639951), CD16 (RRID:AB_2104009), CD56 (RRID:AB_2864402), Ki67 (RRID:AB_1661312), HLA-DR (RRID:AB_964563), granzyme B (RRID:AB_2114697), CD8 (RRID:AB_2075537), CD3 (RRID:AB_2631163), CD4 (RRID:AB_2750883), S100 (RRID:AB_2811056), and PanCytokeratin (RRID:AB_2134432). All antibody clones and manufacturers for The following anti-murine antibodies were used for 